European Commission approves BRAFTOVI and MEKTOVI to treat advanced BRAF-mutant melanoma

Source: Hospital Healthcare Europe, October 2018

The European Commission (EC) had approved the use of BRAFTOVI (encorafenib) and MEKTOVI (binimetinib) to treat adults with advanced BRAF-mutant melanoma.

The EC’s decision is based on results from the Phase 3 COLUMBUS trial, which demonstrated 14.9 months median progression-free survival and 33.6 months median overall survival with the combination therapyversus vemurafenib monotherapy with 7.3 and 16.9 months, respectively.